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A 5-year-old girl presented with acute nocturnal episodes of loss of consciousness
following abdominal pain and crying. Epilepsy was primarily diagnosed but the
course of the disease was suggestive of pulmonary hypertension. An adapted
invasive assessment of pulmonary pressure and pharmacological challenge allowed for
diagnosing vasoreactive pulmonary arterial hypertension. Initial treatment with sildenafil
was not effective. Thus, calcium channel blockers were introduced when positive
vasoreactivity was confirmed and permitted to stop the occurrence of the syncope
and dramatically improved clinical status. At 2 years follow-up she is well without any
complaint and in functional class I. Echocardiography shows a slightly enlarged but
not hypertrophied right ventricle with a nearly normalized estimated right ventricular
pressure. The last catheterization shows subnormal values of pulmonary arterial pressure
(mean pulmonary artery pressure: 24 mmHg) and pulmonary vascular resistance (5,
4 Wood units∗m²), normalizing with inhaled Nitric Oxide (mean pulmonary artery
pressure of 14 mmHg and pulmonary vascular resistance of 1.5 Wood units∗m²).
Vasoreactive pulmonary arterial hypertension is a rare entity in children but it should not
be misdiagnosed with seizures due to the presence of syncopal episodes. According
to current knowledge, this form seems to have a better prognosis than non-reactive
pulmonary arterial hypertension and the treatment of choice remains as calcium channel
blockers. The management of this case was characterized by successive mishaps
and potentially harmful mistakes and underscores the potential risk with pediatric PH
evaluation in non-expert centers.
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Pulmonary arterial hypertension (PAH) in children is a rare and severe disorder with significant
morbidity and mortality (1–6). Despite improvement of its prognosis there is still dismal data
about the longterm outcomes in children (1, 4, 7, 8). The management of pediatric PAH is still
partially based on the adult strategy validated by many pediatric recommendations rather than
controlled studies (1, 3, 4, 7–9). However, international experts tried to find consensus and give
recommendations to best manage children with PAH (1, 3). According to the last guidelines of
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European Society of Cardiology and European Respiratory
Society (ESC/ERS) PAH can be defined as a mean pulmonary
artery pressure (mPAP) higher than 25 mmHg with a normal
pulmonary capillary wedge pressure (PCWP) of ≤15 mmHg
and increased pulmonary vascular resistances index (PVRI) >3
Wood units∗m² (3, 4, 8–11). In addition, values between 20
and 24 mmHg cannot be considered normal and this may be
reconsidered following the last world symposium on pulmonary
hypertension (12). However, this definition may be not easily
applicable to all children but has been accepted in recent pediatric
recommendations (1, 3). The most frequent etiologies of PAH
in the pediatric population, is idiopathic (IPAH), heritable
(HPAH) or associated with congenital heart disease (4, 7, 8).
IPAH or HPAH represents 57% of all PAH registered by the
TOPP (Tracking outcomes and Practice in Pediatric Pulmonary
Hypertension) (1, 7, 9, 10). The estimation of the incidence
for IPAH varies from 0.48 to 0.7 per million children and the
prevalence from 2.1 to 4.4 per million, depending on the country
where the studies were conducted (1).
Vasoreactive PAH is a particular form of PAH, the definition
of which was not based on a clear consensus in children (1, 5,
6, 13–15). Vasoreactivity is defined by the presence of a positive
response to vasodilators at invasive pharmacological challenge (4,
8). The REVEAL-pediatric criteria (modified of BARST criteria)
are most often used in children that request a decrease of at least
20% of the mPAP with unchanged, increased or <10% decreased
CI, and unchanged or decrease pulmonary to systemic vascular
resistance ratio (4, 6, 13, 14, 16). Recently Douwes et al. reported
that the Sitbon criteria (reduction of 10% in the mPAP, reach an
absolute value less or equal than 40 mmHg and unchanged or
increased cardiac output) are the most adapted to determine the
vasoreactivity in children and are the most adapted and selective
for children who will have the best outcome with CCB treatment
(5, 15). Using these criteria allows to observe the same incidence
of vasodilator responders in children and adults, varying from
5 to 17% (5). Earlier, when REVEAL criteria were used, the
incidence of vasodilator responders in children was estimated to
be 10 to 40%, depending on the studies (1, 8, 14, 17–19).
Even if not completely elucidated, pathophysiology of this
disease seems to be consecutive to intracellular pathway
dysfunction resulting in a shift in the vasoactive balance toward
an exaggerated vasoconstrictory response (8–11, 20). In this
particular form of reactive PAH, clinical manifestations may
be related to acute pulmonary hypertensive crises triggered by
several types of stimuli. Unlike other forms of PAH where
the clinical manifestations are mainly due to RV failure and
decreased of exercise capacity. These crises may result in
acute life threatening decrease of cardiac output and syncope.
The paroxysmal nature of vasoreactive PAH crisis renders the
diagnosis challenging. For that reason, diagnosis needs invasive
hemodynamic investigation with acute vasoreactivy testing.
Recently it was suggested at the last PH world symposium
to create a specific subgroup of vasoreactive PAH in the
classification. It is of outmost importance to discriminate the
vasoreactive responders because calcium channel blockers (CCB)
therapy are correlated with an excellent prognosis (1, 3–6).
We describe a 5-year-old girl with a presentation of
vasoreactive PAH. She presented with nocturnal paroxysmal
episodes of loss of consciousness which have first been mistaken
for epileptic seizure.
CASE REPORT
A 5-year-old girl without any contributively family or personal
history was admitted at night to the emergency department
because of an episode of loss of consciousness of a few seconds
that followed abdominal pain, crying and urges. The parents
observed pallor, cyanosis, loss of muscular tone and ocular
revulsion. For a few months, she frequently complained about
abdominal pain with short episodes of absence. Parents also
reported a frequent cough and a reduction of exercise tolerance.
At admission, physical examination shows a systolic
regurgitant murmur. Laboratory investigations showed a slight
metabolic acidosis, increased concentrations of ultrasensitive
Troponin T (65 ng/l) and of liver transaminases (ASAT 82U/l
and ALAT 48U/l). N-terminal pro-Brain Natriuretic Peptide
(NT-Pro-BNP) levels were elevated at 1,024 ng/l (normal value
12–214 ng/l).
Electrocardiogram (ECG) showed an incomplete right bundle
branch block, compatible with a right ventricular hypertrophy.
Echocardiography showed a slight enlargement of the right
ventricle (RV) and right atrium, a tricuspid regurgitation that
allowed the estimation of elevated systolic right ventricular
pressure of more than 45 mmHg and pulmonary artery
dilatation. Putative diagnosis in the emergency department
was a severe seizure equivalent with secondary pulmonary
hypertension and myocardial cell damage due to hypoxemia
and acidosis.
During the next hours, the patient collapsed three times again
since she was monitored. The crisis started with a tachycardia
associated with a decrease of oxygen saturation followed by
bradycardia and tonico-clonical seizures. The patient recovered
spontaneously following the first crisis. Intrarectal diazepam
was given to successfully stop the two other crises. Electro-
encephalography (EEG) was compatible with the presence of
partial epileptic seizures. Cerebral magnetic resonance imaging
was normal. A treatment with valproic acid was started.
Echocardiography was controlled on the next day that confirmed
dilatation of the right cardiac cavities, a tricuspid regurgitation
III/IV and an estimated RV pressure of 55 mmHg (half-systemic)
suggesting the presence of pulmonary hypertension. Sleep
apnea syndrome was excluded by polysomnography. Laboratory
investigations fully normalized at day 2. After improvement
under anti-comitial therapy she was discharged with the putative
diagnosis of frequent partial epileptic seizures responsible for
prolonged hypoxia and pulmonary hypertension.
However, she became increasingly breathless when
exercising, especially at late afternoon and in the evening.
She continuously complained about abdominal pain. Subsequent
echocardiography showed a dilatation of the right atrium and
right ventricle with an estimated RV pressure of 75–80 mmHg.
There was sign of left ventricular compression with a flattening
aspect of the interventricular septum.
Two weeks after the hospital discharge, she was therefore
referred for invasive hemodynamic exploration performed under
general anesthesia. Pulmonary artery pressure was 33 mmHg
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for the systolic, 17 mmHg for the diastolic and 25 mmHg for
the mean pulmonary artery pressure (mPAP) and pulmonary
vascular resistances index (PVRI) were elevated at 4.5 Wood
units ∗m², reaching 58% of systemic values. There was no
fall of pulmonary arterial pressure with 100% of oxygen (O2).
Vasoreactivity testing with inhaled nitric oxide (iNO) was
not performed at that time and treatment with sildenafil was
started at a dose of 10mg 3 times daily (1.5 mg/kg/d). The
valproic acid was switched to levetiracetam. Complete and
exhaustive investigations following current recommendations
were performed to exclude secondary PAH. During hospital
stay, despite treatment with sildenafil and levetiracetam, she had
another episode with tachycardia, loss of consciousness leading
to respiratory arrest and hypotension justifying a transfer to
the intensive care unit. The EEG registered during this incident
showed a lack of electrical activity due to a low cardiac- and
cerebral output. Patient underwent successful resuscitation.
A second invasive hemodynamic study was performed 5 days
later with vasoreactivity testing with iNO showing a significant
decrease of pulmonary arterial pressure and resistances (Table 1).
The mPAP decreased from 31 to 17 mmHg with combination
of O2 and iNO. The CI stayed above 3.5 L/min/m² during
vasoreactivity testing and the PVRI fell from 5.4 to 0.7
Wood units ∗m². Subsequent to the catheterization she was
transferred to the intensive care unit (ICU) with a Swan-Ganz
catheter in place. On ICU she developed another paroxysmal
episode initiated with sinus tachycardia 170 BPM with acute
increase of the systolic PAP of 70 mmHg. Simultaneous
echocardiography showed acute dilation of the right ventricle
(RV) with important D-shape of the interventricular septum
(IVS) and increased systolic RV pressure measured of tricuspid
regurgitation. The episode resolved by administration of iNO
through nasal cannula.
Calcium antagonist diltiazem was added to the treatment.
Initially, there were still some events but progressively less
important and no additional need for iNO administration.
The epileptic treatment was stopped. After a couple of days,
she could be discharged with no more recurrence of syncope.
Diagnosis of vasoreactive PAH with low cardiac output, hypoxia
TABLE 1 | Cardiac catheterization with vasoreactivity testing.
Cardiac catheterization under sildenafil treatment
Baseline O2 100%+NO 20 ppm
PAP(s/d-m) mmHg 45/20/31 25/12/17
Ao(s/d-m) mmHg 83/45/62 76/45/58
PCWP mmHg 12 13
CO L/min 2.5 4
CI L/min/m² 3.5 5.5
PVRI WUm² 5.4 0.7
PAPm/SAPm 0.5 0.29
PAP, pulmonary artery pressure; Ao, aorta; O2, oxygen; NO, inhaled nitric oxide;
s/d-m, systolic/diastolic and mean; PCWP, pulmonary capillary wedge pressure; CI,
cardiac index; PVRI, pulmonary vascular resistance index; PAPm, mean pulmonary artery
pressure; SAPm, mean systemic artery pressure.
and consecutive epileptic seizure was made. The vasodilator
treatment was gradually increased to achieve high doses of
diltiazem (12 mg/kg/d) and sildenafil (3 mg/kg/d).
Two and half years later, the clinical evolution is satisfactory
with no single acute incidents reported and no complaints. The
exercise tolerance is good without any limitation of physical
activity (functional class I). The controlled cardiac MRI showed a
normal function of the right ventricle without sign of dilatation.
Laboratory investigations showed normal concentrations of
ultrasensitive Troponin T (<3 ng/l) and NT-Pro-BNP (78 ng/l).
The pulmonary arterial pressure measured during last cardiac
catheterization was 36/14/24 mmHg and decreased to 19/12/14
under iNO (20 ppm) and O2. PVRI fell from 5.4 to 1.5 Wood
units ∗m². The last 6min walking test showed a walking distance
of 470m without desaturation, considered lower limit for the
age (21). Echocardiography currently shows slight dilation of the
RV with minimal tricuspid regurgitation allowing to measure a
systolic RV pressure of 28 mmHg and good RV function.
DISCUSSION
PAH is a rare but severe disease. Without adequate management,
prognosis remains poor, leading to right ventricular dysfunction
and death (7–9, 11, 13, 16–18, 22). In children, the most frequent
manifestation of PAH is dyspnea on exertion, fatigue and often
syncope during or subsequent to exercise. Less frequent but
not rare symptoms are seizures, chest pain and signs of right
heart failure (2, 8–10, 20). In infant evocative signs of PAH
are tachycardia, loss of appetite, growth retardation and even
lethargy (11).
Our patient shows the particular presentation of nocturnal
paroxysmal convulsive seizures as presenting a form of PAH
which was first mistaken for epileptic seizures. Among the
differential diagnosis of syncope in children, a cardiopulmonary
origin is rare but, as illustrated by our case, it can be the first sign
of PAH. In contrast to adults, children with PAH show syncope
as often as in about 20% of cases (2). In adults with PAH, the
presence of syncope persisting despite treatment is associated
with a higher risk of sudden death. In children with PAH, the
prognostic significance of syncope has still to be established by
longitudinal follow-up studies (2).
The gold standard for the diagnosis of PAH remains
the invasive measurement of hemodynamics with acute
vasoreactivity testing (AVT). This testing is central to determine
treatment strategy (1, 3, 4, 6, 8, 10, 11, 14, 15). The cardiac
catheterization should be done by an experienced pediatric
team to minimize morbidity (1, 3, 5, 6). The TOPP registry
reported a risk of approximately 5.9% of complications. These
complications include pulmonary hypertensive crises, cardiac
arrests, need for inotropic support, arrhythmias and pulmonary
hemorrhage (6, 7).
Recent recommendations underline the importance of
vasoreactivity testing and agree for the treatment by CCB in
case of positive testing. This leads to improvement of WHO
functional class and long term survival in children (1, 5, 7, 8,
10, 11, 14, 19). In line with this, initiation of CCB, in our case
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showed dramatic clinical improvement without any recurrence
of syncope or complaints and normalized hemodynamics at
cardiac catheterization. In our case, vasoreactivity testing was
not performed at first hemodynamic evaluation and thus full
diagnosed was not obtained. Once the diagnosis was established
the use of CCB lead to significant clinical improvement and near
normalization of pulmonary pressures. Vasoreactive patients
should be treated with CCB and there are no data supporting
the use of other vasodilators in this specific subgroup of patients.
The role of acute vasodilatory testing was also described in an
adult patient with severe PAH presenting as recurrent syncope
and severe hemodynamics comprise (23).
In summary, because syncope is a frequently presenting
symptom of pediatric PAH, it should be considered in the
differential diagnosis of syncopal episode. Vasoreactive PAH
must be identified as early as possible to be adequately managed.
Thus, vasoreactivity testing is essential and must be performed in
order to guide treatment. CCB remains the treatment of choice
for vasoreactive responders allowing for excellent outcomes
compared to other forms of PAH. The management of this case
was characterized by successive mishaps and potentially harmful
mistakes and illustrates that pediatric PAH should be diagnosed
and followed up in expert centers.
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